MycoRelic

Sandy Dingo Games · 2025 · $14.99 · Action · deal grade B

Measured on 2026-10-01 16:14 UTC, 4 days ago. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

• Estimated net residual revenue: $353 to $530 per month
• Opportunity: $574 per month at x1.30 dormancy
• Estimated lifetime owners: 6.7k
• 91% positive across 190 reviews · 3.5 reviews/month

Why it's flagged

• Developer active, last post 0 months ago
• Store page localized in only 1 language(s)

Analyst notes (AI-assisted)

Note written 2026-09-11; the live figures above take precedence over any numbers in it.

MycoRelic is an early-access action game with fungal-themed exploration and environmental storytelling, currently in quiet operation with modest but stable residual revenue.

This title sits in a productive middle ground: strong sentiment (90%+), a coherent visual and narrative identity, and genuine player attachment (half still playing despite early-access status), yet it remains invisible to mainstream audiences and generates only baseline residual income. The core audience is small but loyal, and the game's IP is fully owned by Sandy Dingo Games, making it an acquisition-friendly catalog addition or a candidate for a targeted revival campaign. The main friction is balancing difficulty and feature parity (Steam Cloud, achievements, cards) that would unlock broader appeal. Most realistic play: revival.

• Risk: Lack of Steam Cloud, achievements, and trading-card integration limits discoverability and Deck appeal, constraining the addressable audience.
• Risk: Difficulty tuning feedback from co-op players suggests the onboarding experience may be alienating action-game newcomers despite strong environmental appeal.
• Risk: Single-studio operation (one title) raises questions about long-term development capacity and post-acquisition support.

This case as Markdown · Estimates carry ±30-50% error per title.